BetterLife Pharma Inc., an emerging biotechnology company, is advancing its proprietary compound BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), toward human clinical trials. This development comes at a significant time, following recent Phase 2 trial results showing LSD microdosing is ineffective for depression, highlighting the need for alternative approaches in psychedelic-inspired medicine.
The company's compound, BETR-001, maintains its non-hallucinogenic properties even at high doses, as demonstrated in previous publications, and does not induce tolerance with repeated use. This characteristic allows BETR-001 to be administered on a chronic or repeated basis while maintaining effectiveness. Preclinical studies indicate that neuroplastogenic effects require sufficient dosing, and since BETR-001 can be given at full dose without hallucinations, it overcomes a major limitation of traditional psychedelic therapies.
Dr. Ahmad Doroudian, CEO of BetterLife, emphasized the importance of this development. "The importance of being able to give full doses of BETR-001 without hallucinations cannot be over-emphasized," he stated. "Microdosing of psychedelics is often touted as the path forward to avoid the hallucinations of psychedelics full dosing and the need for treatment in specialized clinics with monitoring under special treatment protocols, which require in-clinic time of 8 to 12 hours. BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations."
BetterLife is completing the remaining Investigational New Drug (IND)-enabling studies for BETR-001 and plans to file the IND and begin human clinical trials by the second half of 2026. The initial development scope focuses on treating Traumatic Brain Injury (TBI), cluster headaches, and migraine. The compound also shows potential for treating a broad range of psychiatric disorders, which will be explored as development progresses.
BETR-001's unique characteristics include its non-controlled status, allowing for potential self-administration, unlike regulated psychedelics that require clinical supervision. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent for composition and method of use covers treatment of various neurological disorders until approximately 2042. For further information about the company's developments, visit https://www.blifepharma.com.
The advancement of BETR-001 represents a significant shift in psychedelic-inspired medicine, potentially making effective treatments more accessible by removing the need for specialized clinical settings and lengthy supervision periods. This could dramatically reduce treatment costs and expand access to patients who cannot commit to the intensive protocols required by traditional psychedelic therapies. As the company moves toward clinical trials, the industry watches closely to see if this non-hallucinogenic approach can deliver the therapeutic benefits of psychedelics without their most challenging side effects.
